Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-15
2006-08-15
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S316400, C548S325100, C514S392000
Reexamination Certificate
active
07091232
ABSTRACT:
Compounds of Formula 1where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2Band/or alpha2Cadrenergic receptors in preference over alpha2Aadrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2Badrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.
REFERENCES:
patent: 3996366 (1976-12-01), Baker et al.
patent: 4798834 (1989-01-01), Merritt et al.
patent: 5441970 (1995-08-01), Reitz et al.
patent: 5648373 (1997-07-01), Winkler et al.
patent: 5861420 (1999-01-01), Reitz et al.
patent: 5929103 (1999-07-01), Yoon et al.
patent: 5932742 (1999-08-01), Yoon et al.
patent: 6043373 (2000-03-01), Yoo et al.
patent: 6313172 (2001-11-01), Chow et al.
patent: 6534542 (2003-03-01), Chow et al.
patent: 6545182 (2003-04-01), Chow et al.
patent: 2002/0094998 (2002-07-01), Burke et al.
patent: 1 499 485 (1978-02-01), None
patent: WO 92/0073 (1992-01-01), None
patent: WO 99/28300 (1999-06-01), None
patent: WO 01/00586 (2001-01-01), None
patent: WO 02/36162 (2002-05-01), None
Yoon et al (1998): STN International CAPLUS data base, Columbus (Ohio), Accession No.: 1998: 147327.
Jackman et al (1949): STN International CAPLUS database, Columbus (Ohio), Accession No., 1949: 2664.
Messier et al, Pharmacol. Toxicol., 1995, p. 308-311, 76.
Conklin et al., Nature, 1993, p. 274-276, 363.
Dirig, et al., J. Neurosci. Methods, 1997, p. 183-191, 76.
Hargreaves, et al., Pain, 1988, p. 77-88, 32.
Kim et al., Pain, 1992, p. 355-363, 150.
Dixon et al., Ann. Rev. Pharmacol. Toxicol., 1980, p. 441-462, 20.
Cooke et al., J. Org. Chem., 1980, 45, 1046.
Horne et al., Heterocycles, 1994, 39,139.
Woods et al., J. Amer. Chem. Soc., 1949, 71, 2020.
Sosa et al., J. Org. Chem., 2002, 4498-4500, 67.
Hua et al., J. Org. Chem. 1997, 62, 6888.
Jennesken et al., J. Org. Chem. 1986, 51, 2162.
Kim et al., Synthesis, 1993, 283.
Kowalski et al., J. Org. Chem., 1982, 47, 5088.
Huang et al., Synthetic Communications, 1998, 28, 1197.
Ciufolini et al., J. Amer. Chem. Soc., 1991, 113, 8016.
Mancuso, Synthesis, 1981, p. 165.
Corey et al., Tetrahedron Lett., 1989, 30, 6275.
Xavier et al., Organic Synthesis, 1996, 74, 50.
Molina et al., Tetrahedron, 1995, 51, 1265.
Lemke et al., J. Med. Chem., 1977, 20, 1351.
Berque et al., J. Org. Chem., 1999, 373.
Organ et al., J. Org. Chem., 1997, 62, 1523.
Chow Ken
Garst Michael
Gil Daniel
Gomez Dario G.
Heidelbaugh Todd
Allergan Inc.
Baran Robert J.
Johnson Brent A.
Shameem Golam M. M.
Szekeres Gabor L.
LandOfFree
4-(substituted cycloalkylmethyl) imidazole-2-thiones,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-(substituted cycloalkylmethyl) imidazole-2-thiones,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(substituted cycloalkylmethyl) imidazole-2-thiones,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3716807